Eric S. Langer

President and Managing Partner at BioPlan Associates, Inc. He is also the editor of Advances in Biopharmaceutical Technology in India.

Outsourcing is weighing in more as a tactic for cost-cutting, but it is still not the primary weapon.

BioPlan's Annual Report shows continued growth in the use of single-use technology.

BioPlan's outsourcing survey gives insight on top activities, budgets, and growth trends in biopharmaceutical outsourcing.

Growth is seen in outsourcing of insect- and plant-cell-based bioproduction expression systems.

What the industry's future holds and what needs to be done to get there.

Will international biomanufacturing outsourcing become mainstream in this decade?

Budgets for biopharma activities are gaining in select functional areas, except outsourcing.

Industry wants more innovation, but can suppliers meet customers' needs?

A review of key industry shifts and promises for the future.